Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Status:
Recruiting

Trial end date:
2023-12-15

Target enrollment:

Participant gender:

To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.

Phase 2

Stanford University